Gaize Revolutionizes Impairment Detection with Groundbreaking Patent Award
Gaize Logo
Gaize Headset
The patent awarded to Gaize is a significant piece of validation for the company's unique approach to impairment detection from cannabis and other drugs.
"This patent is huge piece of validation," said Ken Fichtler, CEO of Gaize. "Gaize has built a scientifically validated, objective method for determining impairment that goes beyond traditional, chemical-based testing. This means employers and law enforcement can now make informed decisions based on a person's current state, not what they may have consumed hours or even days ago."
Gaize's technology utilizes a virtual reality headset equipped with high-precision eye tracking sensors. During a quick, six-minute test, users follow moving targets with their eyes while the system analyzes their eye movements and pupil characteristics. Gaize's AI algorithms then compare the data to a vast database of impairment indicators, providing an instant clear result: either signs of impairment are found, or signs of impairment are absent.
The potential benefits of this technology are vast. For employers, Gaize offers a reliable and non-invasive way to ensure workplace safety while minimizing the risk of discrimination or false positives. Since Gaize is sensitive to impairment from a vast number of substances, employers are no longer limited to looking for the mere presence of a select few substances. Law enforcement can use it to improve training, in roadside sobriety testing and to gather objective evidence for DUI investigations.
"We are committed to making our roads and workplaces safer for everyone," said Rob Lass, CTO of Gaize. "This patent is a significant step forward in that mission, and we are excited to continue innovating and bringing this life-saving technology to the world."
Key benefits of Gaize's patented impairment detection technology:
• Objective and accurate: Analyzes eye movements to detect signs of impairment, not just presence of substances.
• Fast and efficient: Delivers results in just six minutes, allowing for immediate action.
• Non-invasive and private: No bodily fluids, no personal information or embarrassing procedures.
• Scientifically validated: Backed by decades of research on eye movement and impairment.
• Versatile: Applicable to a wide range of substances, not just those on standard 5 or 12-panel drug tests.
Ken Fichtler
Gaize, Inc.
+1 4065181894
support@gaize.ai
Visit us on social media:
Facebook
Twitter
LinkedIn
Instagram
YouTube
EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.
